Scarica l'app Stockscreener
4.56
8.06%
-0.40
Precedente Chiudi:
$4.96
Aprire:
$4.91
Volume 24 ore:
278.57K
Relative Volume:
0.62
Capitalizzazione di mercato:
$34.98M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-6.9091
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
-15.24%
1M Prestazione:
-3.39%
6M Prestazione:
-53.85%
1 anno Prestazione:
-60.10%
Intervallo 1D:
$4.55
$5.00
Intervallo di 1 settimana:
$4.55
$5.545
Portata 52W:
$3.61
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Confronta DTIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.56 | 34.98M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Geode Capital Management LLC Raises Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) - Defense World
Precision BioSciences (NASDAQ:DTIL) Earns “Buy” Rating from HC Wainwright - Defense World
Precision BioSciences (NASDAQ:DTIL) Raised to “Outperform” at BMO Capital Markets - Defense World
BMO Capital Upgrades Precision BioSciences (DTIL) - MSN
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst - Benzinga
Precision BioSciences Shares Surge 60% After Breakthrough Clinical Results for OTC Deficiency Treatment - HPBL
Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha
Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward - Investing.com Canada
Pre-Market Surge For Precision BioSciences (DTIL) On Groundbreaking Trial Data - Stocks Telegraph
Precision BioSciences shares soar on promising gene editing trial results By Investing.com - Investing.com Australia
Precision BioSciences shares soar on promising gene editing trial results - Investing.com
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - BioSpace
DTILPrecision BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease - The Scientist
Precision BioSciences Gene Therapy Shows Breakthrough Success in Infant OTC Deficiency Trial - StockTitan
Precision BioSciences projects extended cash runway into 2026 - Investing.com
Precision Biosciences director Germano purchases $16,186 in stock By Investing.com - Investing.com Canada
Insider Buying: Geno Germano Acquires Shares in Precision BioSci - GuruFocus.com
Precision Biosciences director Germano purchases $16,186 in stock - Investing.com
Precision BioSciences stock hits 52-week low at $4.12 By Investing.com - Investing.com Canada
Precision Biosciences director Kevin Buehler buys $21,081 in stock By Investing.com - Investing.com Nigeria
Precision BioSciences stock hits 52-week low at $4.12 - Investing.com India
Precision Biosciences CFO buys $10,036 in common stock By Investing.com - Investing.com Canada
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSc - GuruFocus.com
Insider Buying: John Kelly Acquires Shares of Precision BioScien - GuruFocus.com
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):